The Sen lab is focused on the development of new treatment paradigms for molecular subsets of lung cancer

Situated in the Icahn School of Medicine at the Mount Sinai Medical Center in New York City, the Sen lab is taking a multidisciplinary approach to understand tumor progression, immune modulation, phenotypic plasticity and therapy resistance in lung cancer. The aim is to translate fundamental discoveries in the lab into more effective and durable treatments for patients.

The Sen Lab uses intricate tumor models and advanced approaches to study clinically relevant molecular subsets of lung cancer.

Major Subtypes of Lung Cancer
Lung cancer is the leading cause of cancer-related death in the United States and is divided into two major subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
NSCLC accounts for about 80% of lung cancer diagnosis, which are typically adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.
SCLC is a high-grade neuroendocrine cancer that accounts for 20% of lung cancers and is typically metastatic at diagnosis. Annually, SCLC causes more than 200,000 deaths worldwide, ~30,000 deaths in the United States, has a dismal median overall survival of approximately one year, and a two-year survival rate below 5% for advanced disease. There are currently no targeted therapies approved for SCLC patients beyond the recent approval of immunotherapy, which only benefits a small percentage of patients. Drug resistance, both inherent and acquired, is a major problem preventing effective lung cancer treatment.